PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity

By sjmartinez • November 27, 2024

Varuzhanyan G, Chen CC, Freeland J, He T, Tran W, Song K, Wang L, Cheng D, Xu S, Dibernardo GA, Esedebe FN, Bhatia V, Han M, Abt ER, Park JW, Memarzadeh S, Shackelford DB, Lee JK, Graeber TG, Shirihai OS, Witte ON. PGC-1α drives small cell neuroendocrine cancer progression toward an ASCL1-expressing subtype with increased mitochondrial capacity. Proc Natl Acad Sci U S A. 2024 Dec 3;121(49):e2416882121. doi: 10.1073/pnas.2416882121. Epub 2024 Nov 26. PMID: 39589879.

Tags: ASCL1, Endocrinology, Hematology/Oncology, Lung cancer, Oxidative phosphorylation, PGC-1a, prostate cancer, Publications, Pulmonary, Critical Care & Sleep Medicine

Compartment-Specific Recurrence in Medullary Thyroid Cancer

Seo YJ, Larios KN, Mao YV, Elkersh YK, England B, Hughes EG, Lim AN, Kim J, Livhits MJ, Yeh MW, Angell TE, Hu-Bianco QL, Lee[...]

A Case of Thyroid Dermopathy

Day AJ, Sarantopoulos GP. A Case of Thyroid Dermopathy. Cureus. 2026 Jul 29;18(7):e113624. doi: 10.7759/cureus.113624. PMID: 42668724; PMCID: PMC13525185.

Afirma Xpression Atlas Alteration Status Is Associated with Malignancy Risk in Indeterminate Thyroid Nodules

Peng TD, Hughes EG, Kim J, Tseng CH, SmookePraw S, Wu JX, Yeh MW, Livhits MJ. Afirma Xpression Atlas Alteration Status Is Associated with Malignancy[...]